BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38259203)

  • 21. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
    Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
    J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor-Positive Breast Cancer: A Multicohort Study.
    Fan M; Cui Y; You C; Liu L; Gu Y; Peng W; Bai Q; Gao X; Li L
    Radiology; 2022 Mar; 302(3):516-524. PubMed ID: 34846204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
    Arasu VA; Miglioretti DL; Sprague BL; Alsheik NH; Buist DSM; Henderson LM; Herschorn SD; Lee JM; Onega T; Rauscher GH; Wernli KJ; Lehman CD; Kerlikowske K
    J Clin Oncol; 2019 Apr; 37(12):954-963. PubMed ID: 30625040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
    Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
    Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
    Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
    J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores.
    Nam KJ; Park H; Ko ES; Lim Y; Cho HH; Lee JE
    Medicine (Baltimore); 2019 Jun; 98(23):e15871. PubMed ID: 31169691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrafast DCE-MRI for discriminating pregnancy-associated breast cancer lesions from lactation related background parenchymal enhancement.
    Nissan N; Anaby D; Mahameed G; Bauer E; Moss Massasa EE; Menes T; Agassi R; Brodsky A; Grimm R; Nickel MD; Roccia E; Sklair-Levy M
    Eur Radiol; 2023 Nov; 33(11):8122-8131. PubMed ID: 37278853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    Watt GP; Sung J; Morris EA; Buys SS; Bradbury AR; Brooks JD; Conant EF; Weinstein SP; Kontos D; Woods M; Colonna SV; Liang X; Stein MA; Pike MC; Bernstein JL
    Breast Cancer Res; 2020 Dec; 22(1):138. PubMed ID: 33287857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.
    Thakur SB; Durando M; Milans S; Cho GY; Gennaro L; Sutton EJ; Giri D; Morris EA
    J Magn Reson Imaging; 2018 Feb; 47(2):401-409. PubMed ID: 28640531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Background Parenchymal Enhancement at Contrast-Enhanced Spectral Mammography (CESM) as a Breast Cancer Risk Factor.
    Sorin V; Yagil Y; Shalmon A; Gotlieb M; Faermann R; Halshtok-Neiman O; Sklair-Levy M
    Acad Radiol; 2020 Sep; 27(9):1234-1240. PubMed ID: 31812577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast MRI Background Parenchymal Enhancement Categorization Using Deep Learning: Outperforming the Radiologist.
    Eskreis-Winkler S; Sutton EJ; D'Alessio D; Gallagher K; Saphier N; Stember J; Martinez DF; Morris EA; Pinker K
    J Magn Reson Imaging; 2022 Oct; 56(4):1068-1076. PubMed ID: 35167152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
    Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gadoteridol-enhanced MRI of the breast: can contrast agent injection rate impact background parenchymal enhancement?
    Marzocca F; Moffa G; Landi VN; Panzironi G; Kirchin MA; Pediconi F; Galati F
    Acta Radiol; 2022 Sep; 63(9):1173-1179. PubMed ID: 34323589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study.
    Tsukada H; Tsukada J; Ochi T; Noguchi E; Okamoto T
    Ann Nucl Med; 2022 Oct; 36(10):853-864. PubMed ID: 35819628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI.
    Hellgren R; Saracco A; Strand F; Eriksson M; Sundbom A; Hall P; Dickman PW
    Acta Radiol; 2020 Dec; 61(12):1600-1607. PubMed ID: 32216451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Lesion Conspicuity and Size Assessment according to Background Parenchymal Enhancement.
    Kim SY; Cho N; Choi Y; Shin SU; Kim ES; Lee SH; Chang JM; Moon WK
    Korean J Radiol; 2020 May; 21(5):561-571. PubMed ID: 32323501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic contrast-enhanced breast magnetic resonance imaging for the prediction of early and late recurrences in breast cancer.
    Choi EJ; Choi H; Choi SA; Youk JH
    Medicine (Baltimore); 2016 Nov; 95(48):e5330. PubMed ID: 27902592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fully Automatic Assessment of Background Parenchymal Enhancement on Breast MRI Using Machine-Learning Models.
    Nam Y; Park GE; Kang J; Kim SH
    J Magn Reson Imaging; 2021 Mar; 53(3):818-826. PubMed ID: 33219624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.